Cancer Treatment Reviews
Volume 35, Issue 8 , Pages 662-667 , December 2009

The role of topoisomerase IIα and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients

  • Catherine Oakman

      Affiliations

    • These authors have contributed equally to this manuscript.
    • ,
  • Erica Moretti

      Affiliations

    • These authors have contributed equally to this manuscript.
    • ,
  • Francesca Galardi
    • ,
  • Libero Santarpia
    • ,
  • Angelo Di Leo

      Affiliations

    • Corresponding Author InformationCorresponding author. Address: ‘Sandro Pitigliani’ Medical Oncology Unit, Department of Oncology, Hospital of Prato, Istituto Toscano Tumori, Piazza Ospedale 2, 59100 Prato, Italy. Tel.: +39 0574 434766; fax: +39 0574 29798.

Received 12 June 2009 ,Revised 6 August 2009 ,Accepted 7 August 2009.

References 

  1. Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687–717.
  2. Treszezamsky AD, Kachnic LA, Feng Z, et al. BRCA1- and BRCA2-deficient cells are sensitive to etoposide-induced DNA double-strand breaks via topoisomerase II. Cancer Res. 2007;67:7078–7081
  3. Sauter G, Lee J, Bartlett J, Slamon D, Press M. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol. 2009;8:1323–1333
  4. Dhesy-Thind B, Pritchard KI, Messersmith H, et al. HER-2/neu in systemic therapy for women with breast cancer: a systemic review. Breast Cancer Res Treat. 2008;109:209–229
  5. Gennari A, Sormani MP, Pronzato P, et al. HER-2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl Cancer Inst. 2008;100:14–20
  6. DeVita V, Lawrence T, Rosenberg S. DeVita, Hellman, and Rosenberg’s cancer: principles & practice of oncology. 8th ed.. Philadelphia, PA: Lippincott Williams and Wilkins; 2008;
  7. Isaacs RJ, Davies SL, Sandi MI, et al. Physiological regulation of eukaryotic topoisomerase II. Biochim Biophys Acta. 1998;1400:121–137
  8. Goswami PC, Sheren J, Albee LD, et al. Cell cycle-coupled variation in topoisomerase II alpha mRNA is regulated by the 3′-untranslated region. Possible role of redox sensitive protein binding in mRNA accumulation. J Biol Chem. 2000;275:383384–383392
  9. Durbecq V, Desmedt C, Paesmans M, et al. Correlation between topoisomerase-II alpha gene amplification and protein expression in HER-2 amplified breast cancer. Int J Oncol. 2004;25:1473–1479
  10. Mueller RE, Parkes RK, Andrulis I, et al. Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples. Genes Chromosomes Cancer. 2004;39:288–297
  11. Callagy G, Pharoah P, Chin SF, et al. Identification and validation of prognostic markers in breast cancer with complementary use of array-CGH and tissue microarrays. J Pathol. 2005;205:388–396
  12. Jarvinen TA, Holli K, Kuukasjärvi T, et al. Predictive value of topoisomerase II alpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer. Br J Cancer. 1998;77:2267–2273
  13. Jarvinen TA, Kononen J, Pelto-Huikko M, et al. Expression of topoisomerase II alpha is associated with rapid cell proliferation, aneuploidy, and c-erbB2 over expression in breast cancer. Am J Pathol. 1996;148:2073–2082
  14. Nakopoulou L, Lazaris AC, Kavantzas N, et al. DNA topoisomerase II-alpha immunoreactivity as a marker of tumor aggressiveness in invasive breast cancer. Pathobiology. 2000;68:137–143
  15. Di Leo A, Moretti E. Anthracyclines: the first generation of cytotoxic targeted agents? A possible dream. J Clin Oncol. 2008;31:5027–5035
  16. Mo YY, Beck WT. Heterogeneous expression of DNA topoisomerase II alpha isoforms in tumor cell lines. Oncol Res. 1997;9:193–204
  17. Mirski SE, Bielawski JC, Cole SP. Identification of functional nuclear export sequences in human topoisomerase II alpha and beta. Biochem Biophys Res Commun. 2003;306:905–911
  18. Turner JG, Engel R, Derderian JA, et al. Human topoisomerase II alpha nuclear export is mediated by two CRM-1-dependent nuclear export signals. J Cell Sci. 2004;117:3061–3071
  19. Oloumi A, MacPhail SH, Johnston PJ, et al. Changes in subcellular distribution of topoisomerase II alpha correlate with etoposide resistance in multicell spheroid and xenograft tumours. Cancer Res. 2000;60:5747–5753
  20. Ernst AI, Soltermann A, Sigrist JA, et al. Ectopic expression of human topoisomerase II alpha fragments and etoposide resistance in mammalian cells. Int J Cancer. 2000;88:99–107
  21. Jarvinen TA, Liu ET. HER-2/neu and topoisomerase II alpha in breast cancer. Breast Cancer Res Treat. 2003;78:299–311
  22. Beser AR, Tuzlali S, Guzey D, et al. HER-2, TOP2A and chromosome 17 alterations in breast cancer. Pathol Oncol Res. 2007;13:180–185
  23. Bofin AM, Ytterhus B, Hagmar BM. TOP2A and HER-2 gene amplification in fine needle aspirates from breast carcinomas. Cytopathology. 2003;14:314–319
  24. Slamon DJ, Mackey J, Robert N, et al. Role of anthracycline-based therapy in the adjuvant treatment of breast cancer: efficacy analyses determined by molecular subtypes of the disease. San Antonio Breast Cancer Sympos 2007:13 [abstract].
  25. O’Malley F, Chia S, Tu D, et al. Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst. 2009;101:644–650
  26. Gennari A, Sormani M, Pfeffer U, et al. TOP mRNA expression in HER2 negative breast cancer. San Antonio Breast Cancer Sympos 2008:6036 [abstract].
  27. McArthur HL, Tan LK, Patil S, et al. High resolution representational oligonucleotide microarray analysis (ROMA) suggests that TOPO2 and HER2 coamplification is uncommon in human breast cancer. San Antonio Breast Cancer Sympos 2009:69 [abstract].
  28. Paik S, Bryant J, Park C, et al. ErbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst. 1998;90:1361–1370
  29. Thor AD, Berry DA, Budman DR, et al. ErbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst. 1998;90:1346–1360
  30. Di Leo A, Gancberg D, Larsimont D, et al. HER-2 amplification and topoisomerase II alpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res. 2002;8:1107–1116
  31. Tanner M, Isola J, Wiklund T, et al. Topoisomerase IIa gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Cancer Group Trial 9401. J Clin Oncol. 2006;24:2428–2436
  32. Paik S, Taniyama Y, Geyer C. Anthracyclines in the treatment of HER2-negative breast cancer. J Natl Cancer Inst. 2008;100:6–8
  33. De Laurentiis M, Caputo F, Massarelli E, et al. HER2 expression and anthracycline effect: results from the Naples GUN3 randomised trial. Proc Am Assoc Cancer Res 2001:133 [abstract].
  34. Pritchard KI, Shepherd LE, O’Malley FP, et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. New Engl J Med. 2006;354:2103–2111
  35. Barlett JMS, Munro AF, Cameron DA, et al. Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trials. J Clin Oncol. 2008;26:5027–5035
  36. Slamon D, Eiermann W, Robert N, et al. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2neu positive early breast cancer patients. San Antonio Breast Cancer Sympos 2006:52 [abstract].
  37. Knoop AS, Knudsen H, Baslev E, et al. Retrospective analysis of topoisomerase 2a amplification and deletion as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol. 2005;23:7483–7490
  38. Bartlett JMS, Munro A, Dunn JA, et al. Chromosome 17 polysomy (Ch17) as a predictor of anthracycline response: emerging evidence form the UK NEAT adjuvant breast cancer trial. San Antonio Breast Cancer Sympos 2008:45 [abstract].
  39. Harris LN, Broadwater G, Abu-Khalaf M, et al. Topoisomerase IIα amplification does not predict benefit from dose–intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013. J Clin Oncol. 2009;21:3430–3436
  40. Desmedt C, Azambuja E, Larsimont D, et al. Predicting the efficacy of anthracyclines in breast cancer (BC) patients: results of the neoadjuvant TOP trial. Proc Am Soc Clin Oncol 2009:523 [abstract].
  41. Burgess D, Doles J, Zender L, et al. Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc Natl Acad Sci USA. 2008;105:9053–9058
  42. Di Leo A, Isola J, Piette F, et al. A meta-analysis of phase III trials evaluating the predictive value of HER2 and topoisomerase II alpha in early breast cancer patients treated with CMF or anthracycline-based adjuvant therapy. San Antonio Breast Cancer Sympos 2008:705 [abstract].
  43. Orlando L, Del Curto B, Gandini S, et al. Topoisomerase II alpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive HER2/neu-positive breast cancer. Breast. 2008;17:506–511
  44. <http://clinicaltrials.gov/ct2/show/NCT00493870>.
  45. Reinholz MM, Bruzek AK, Visscher DW. Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response. Lancet Oncol. 2009;10:267–277
  46. Ejlertsen B, Jensen M-B, Nielsen KV, et al. TOP2A, TIMP-1 and responsiveness to adjuvant anthracycline containing chemotherapy in high risk breast cancer patients. San Antonio Breast Cancer Sympos 2008:36 [abstract].
  47. Farmer P, Bonnefoi H, Anderle P, et al. A stroma-related gene signature predicts response to neoadjuvant chemotherapy in breast cancer. Nature Med. 2009;1:68–74

PII: S0305-7372(09)00121-2

doi: 10.1016/j.ctrv.2009.08.006

Cancer Treatment Reviews
Volume 35, Issue 8 , Pages 662-667 , December 2009

Article Tools

* Image Usage & Resolution